Liquid biopsy for diagnosing glioma tumors
The circTeloDIAG: a New Approach of Liquid Biopsy for the Diagnosis and Follow-up of Patients With Glioma Tumor
Hospices Civils de Lyon · NCT04931732
This study is testing if a simple blood test can help doctors find and understand glioma brain tumors better, making it easier to decide on the right treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Hospices Civils de Lyon (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bron) |
| Trial ID | NCT04931732 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the use of liquid biopsy to detect glioma-specific oncogenic processes in peripheral blood, particularly through the analysis of circulating tumor DNA (ctDNA). Gliomas are the most common primary brain tumors, and their diagnosis is crucial for effective patient management. The study aims to refine glioma diagnosis by identifying molecular biomarkers that can aid in differentiating tumor grades and guiding treatment decisions. By utilizing liquid biopsy, the study seeks to establish a routine clinical testing method for gliomas, which currently lacks standardized approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with suspected newly or recurrent glioma (grade II or higher) who are eligible for surgical intervention.
Not a fit: Patients with suspected grade I tumors or those who refuse surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of gliomas, improving treatment outcomes for patients.
How similar studies have performed: While liquid biopsy has shown promise in other cancers, its application for gliomas is still novel and untested in routine clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient * Obtainment of written informed consent * Suspected newly or recurrent glioma (grade ≥ II) on MRI * Patient eligible for surgery (biopsy or resection) * Decision of surgery (biopsy or resection) at neuro-oncology interdisciplinary tumor board Exclusion Criteria: * Rejection of consent by patient * Hemoglobin \< 7g/dl * Rejection of surgery by patient * Suspected grade I tumor on MRI
Where this trial is running
Bron
- East Group Hospital, Hospices Civils de Lyon — Bron, France (RECRUITING)
Study contacts
- Study coordinator: GARNIER Louis, Dr
- Email: louis.garnier@chu-lyon.fr
- Phone: +33 (0)4 72 68 13 59
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, liquid biopsy, glioma, pseudoprogression, relapse